“A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma”, Hematol Meeting Rep, vol. 2, no. 5, Jun. 2009, doi: 10.4081/hmr.v2i5.725.